STEP 2: Spasticity Live Course - November 10-11, 2026, in Orlando, FL

This is part of the full STEP Interventional Spasticity Certificate Program. The STEP Interventional Spasticity Certificate Program is a multi-tiered training program that teaches and assesses concussion management using a progressive, competency-based curriculum. 

Registration Information

Register now for the November 2026 in-person STEP Two spasticity course, which is part of the full STEP Interventional Spasticity Certificate Program. The STEP Interventional Spasticity Certificate Program is a multi-tiered training program that teaches and assesses concussion management using a progressive, competency-based curriculum. Once registered, you will have access to the STEP 1: Online Program, STEP 2: Live Course, and STEP 3: Assessment and Certificate. For complete details, click HERE.

Description

Take the Next STEP in Your Spasticity Education
AAPM&R is arming members with training to help them prepare and lead in competitive landscapes. Following the success of the highly-acclaimed STEP Ultrasound Certificate Program, we are excited to announce the launch of the STEP Interventional Spasticity Certificate Program.

STEP stands for Skills, Training, Evaluation and Performance. The STEP Interventional Spasticity Certificate Program teaches and assesses interventional spasticity skills using a standardized, progressive, and competency-based curriculum with both online and live components.

When you earn the STEP Interventional Spasticity Program Certificate, you:
  • Gain confidence by representing the highest standard in the field
  • Enhance your career opportunities
  • Earn visibility and credibility in spasticity management
  • Communicate to patients and employers that you are committed to excellence
  • Earn AMA PRA Category 1 Credits™ and meet American Board of Physical Medicine and Rehabilitation (ABPMR) Maintenance of Certification® (MOC®) Part II and Part IV requirements

Learning Objectives
After completion of the STEP Interventional Spasticity Program, participants should be able to:

  • Have in-depth understanding of spasticity and its impact on patients
    Assess the advantages and disadvantages of all treatment options (i.e., pumps, oral medications, surgeries)
    Synthesize an optimal dynamic treatment plan for spasticity interventions
    Discuss the pharmacology of injectable agents
    Prepare and administer injectable toxins and nerve blocks
    Recognize and assess functional anatomy related to spasticity (i.e., motion analysis)
    Utilize multiple localization methods (EMG, US, hands/eyes, muscles, landmarks) for chemodenervation and nerve blocks
    Recognize appropriate candidates for targeted drug delivery
    Perform basic pump programming (increase/decrease, bridge bolus) on the most commonly used delivery systems
    Recognize the utility of complex pump programming
    Handle ITB emergencies
    Identify the resources necessary to establish, manage, and grow a spasticity practice

Prerequisites
Recommended prerequisites for successful completion of the program are:

  • At least 3 years of PM&R residency. 4th year PM&R residents may participate but should have their ACGME-required 20 toxin injections and 10 US scanning completed.
  • Some familiarity with ultrasound and EMG principles.
  • A sound working knowledge of MSK anatomy and kinesiology.
STEP Details
The program consists of three steps, which must be completed in the order as outlined below.
  1. STEP 1: Online Program - Accessable Now
    1. Baseline Pre-Exam with 25 Questions
    2. Online Curriculum - 16 CME Credits
  2. STEP 2: Live Course - November 10-11, 2026, in Orlando, FL
    1. Step Two: Interventional Spasticity Management Applications Live Course, 15.25 CME Credits
    2.  Online Post-Exam with 25 Questions
    3. Case Log
  3. STEP 3: Assessment and Certificate 
    1. Online Final Post-Exam with 50 Questions
    2. In-Person Skills Assessment November 2027 in Phoenix, AZ
Accreditation

Accreditation Statement 
The American Academy of Physical Medicine and Rehabilitation (AAPM&R) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

CME Credit Designation 
STEP 1 - Online Program 

The American Academy of Physical Medicine and Rehabilitation (AAPM&R) designates this enduring material for a maximum of 16 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

STEP 2 - Live Course 
The American Academy of Physical Medicine and Rehabilitation (AAPM&R) designates this live activity for a maximum of 15.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The live course has also been approved by the American Board of Physical Medicine and Rehabilitation (ABPMR) for a maximum of 15.25 Maintenance of Certification® (MOC®) Part II Self-Assessment credits. Attendees must actively participate and complete a self-evaluation at the conclusion of the course to earn MOC Part II credit.

STEP 3 - Assessment and Certificate
Completion of the entire program, which includes passing the assessment and submitting your case log, will count towards your American Board of Physcial Medicine and Rehabilitation MOC Part IV requirements.  

Disclosure Statement 
In accordance with ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, AAPM&R requires all individuals who are in a position to affect the strategic direction of AAPM&R and/or control the content of an educational activity to disclose all financial relationships with any ineligible company within the last 24 months. The ACCME defines an “ineligible company” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.  

Disclosures are made in written form prior to the start of the educational activity, and any potential conflicts of interest that exist are mitigated prior to the start of the activity through AAPM&R’s Conflict of Interest Disclosure and Resolution Policy Process. Individuals in a position to affect the strategic direction of AAPM&R and/or control content and their disclosed financial relationships are listed below. 

No other planners, faculty, or individuals in control of content disclosed any relevant financial relationships. Through the planning process, all relevant financial relationships have been mitigated. 

STEP Spasticity Workgroup 
Roy L. Adair, MD: Disclosed no relevant financial relationships 
Abraham Alfaro, PhD, DO: Disclosed no relevant financial relationships 
Katharine E. Alter, MD: Disclosed no relevant financial relationships 
Keith D Baldwin, MD, MSPT, MPH: Pfizer: Stock Options
Gerald S. Bilsky, MD: Medtronic and Saol Pharmaceuticals: Speakers' Bureau
Kristin E. Caldera, DO: Medtronic: Speakers' Bureau
Jeimylo C. de Castro, MD: Disclosed no relevant financial relationships 
Jennifer E. Doble, MD: Disclosed no relevant financial relationships 
Franklin SP Domingo, MD: Disclosed no relevant financial relationships 
Steve V. Escaldi, DO: Saol Pharmaceuticals: Consultant 
Alberto Esquenazi, MD: Disclosed no relevant financial relationships 
Reza Farid, MD: Disclosed no relevant financial relationships 
Nicholas A. Godby, MD: Disclosed no relevant financial relationships 
Fatma Gul, MD: Disclosed no relevant financial relationships 
Shivani Gupta, DO: Disclosed no relevant financial relationships 
Ryan C. Hafner, MD: Disclosed no relevant financial relationships 
Patricia J. Hantsch, MD: Disclosed no relevant financial relationships 
Kimberly Heckert, MD: Merz Therapeutics, Piramal, and Saol Pharmaceuticals: Spasticity fellowship program received educational grants
Didem Inanoglu, MD: Ipsen: Trainer/Faculty and Consultant; Allergan: Consultant, Advisory Board
Cindy B. Ivanhoe, MD: Disclosed no relevant financial relationships 
Mary Ann Keenan, MD: Disclosed no relevant financial relationships 
Nicholas C. Ketchum, MD: Medtronic: Speakers' Bureau and Consulting; Saol Pharmaceuticals: Consulting
Heakyung Kim, MD: Disclosed no relevant financial relationships 
Linda E. Krach, MD: Disclosed no relevant financial relationships 
Christina Kwasnica, MD: Ipsen Pharmaceuticals Speakers’ Bureau
John Lin, MD: Disclosed no relevant financial relationships 
Sheng Li, MD PhD: Disclosed no relevant financial relationships 
Amy A. Mathews, MD: Disclosed no relevant financial relationships 
John R. McGuire, MD: Disclosed no relevant financial relationships 
Daniel K. Moon, MD: Disclosed no relevant financial relationships 
Marisa Moreta, DO: Disclosed no relevant financial relationships 
Michael C. Munin, MD: Disclosed no relevant financial relationships 
Patricia Nance, MD: Disclosed no relevant financial relationships 
Marilyn S. Pacheco, MD: Disclosed no relevant financial relationships 
Atul T. Patel, MD, MHSA: Allergan and Ipsen Research: Grants and Speakers' Bureau
Natasha L. Romanoski, DO: Disclosed no relevant financial relationships 
Michael F. Saulino, MD PhD: Disclosed no relevant financial relationships 
Mary E. Russel, DO, MS: Merz Therapeutics and Allergan Speakers' Bureau
Erik T. Shaw, DO: TerSera Therapeutics, Boston Scientific, and SPR Therapeutics: Consultant; BDSI: Speakers' Bureau
Andrea P. Toomer, MD: Flowonix and Ipsen Biopharmaceuticals: Research/Speakers Bureau; Medtronic and Piramal: Speakers Bureau
Jose A. Urquidez, MD: Disclosed no relevant financial relationships 
Monica Verduzco-Gutierrez, MD: AbbVie and Merz Therapeutics: Consultant/Speakers' Bureau; Ipsen Biopharmaceuticals: Consultant/Research Grant/Speakers' Bureau
Heather W. Walker, MD: Disclosed no relevant financial relationships 
Thomas K. Watanabe, MD  : Disclosed no relevant financial relationships 

AAPM&R Medical Education Committee
Name, Credential(s): Company Name, Nature of financial relationship
Rachel Brakke Holman, MD - Nothing to Disclose                                            
Sarah M. Eickmeyer, MD - Nothing to Disclose                                            
Chelsea D. Frost, MD, MS - Nothing to Disclose                                            
David J. Haustein, MBA,MD,MBA - PM Consulting, Ownership or Partnership; Expert Medical Consulting, Ownership or Partnership; Greene County Medical Society Executive Council; Non-remunerative Positions of Influence, Missouri State Medical Foundation Board; Non-remunerative Positions of Influence, Vice President of the Missouri State Medical Society; Non-remunerative Positions of Influence
Sarah K. Hwang, MD - Nothing to Disclose                                            
Ravi E. Kasi, MD - Nothing to Disclose                                            
Caroline Pupke, DO - Nothing to Disclose                                            
Monica E. Rho, MD - Nothing to Disclose                                            
McCasey R. Smith, MD - Nothing to Disclose                                            
Jennifer A. Soo Hoo, MD - Nothing to Disclose                                            
Brionn K. Tonkin, MD - Nothing to Disclose                                            
Stephanie Tow, MD - US Paralympics Swimming Team Head Physician, Volunteer; United States Olympic & Paralympic Committee,    Honorarium                        
Justin L. Weppner, DO - Nothing to Disclose                                            
Alexandra G. Wolfe, DO - Nothing to Disclose   

AAPM&R CME Committee:
Brionn K. Tonkin, MD, Chair: Disclosed no relevant financial relationships.
Leah G. Concannon, MD: Disclosed no relevant financial relationships.
Cherry C. Junn, MD: Disclosed no relevant financial relationships.
Tracy M. Paul, MD: Disclosed no relevant financial relationships.
Cynthia G. Pineda, MD: Disclosed no relevant financial relationships.
Jeremy Roberts, MD: Disclosed no relevant financial relationships.
Peter C. Yeh, MD: Disclosed no relevant financial relationships.

FDA Disclosures 
Any faculty member for this activity who intends to discuss or demonstrate any pharmaceutical or medical device for which FDA clearance has not been approved, will verbally disclose the FDA’s classification at the beginning of their presentation or demonstration.  

Summary
Availability:
Registration Required
(21 seats available)
Location:
HYATT REGENCY ORLANDO (Headquarters Hotel)
9801 International Drive
Orlando, FL 32819
Date / Time:
Nov 10 - Nov 11, 2026 ET
Cost:
Member: $2,500.00
Non-Member: $3,500.00
Resident Member: $2,500.00
Resident Non-Member: $3,500.00
Credit Offered:
No Credit Offered
Android App Download IOS App Download Powered By